Antony D Loebel

Summary

Publications

  1. ncbi request reprint Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study
    Antony D Loebel
    Pfizer Inc, New York, NY 10018, USA
    J Clin Psychiatry 68:1333-8. 2007
  2. ncbi request reprint Effect of initial ziprasidone dose on length of therapy in schizophrenia
    Amie T Joyce
    PharMetrics, Inc, 311 Arsenal Street, Watertown, MA 02472, USA
    Schizophr Res 83:285-92. 2006
  3. ncbi request reprint Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia
    C Daniel Mullins
    University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    Schizophr Res 98:8-15. 2008
  4. ncbi request reprint Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    Peter J Weiden
    Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Neuropsychopharmacology 33:985-94. 2008
  5. ncbi request reprint The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists
    John W Newcomer
    Department of Psychiatry and Psychology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychopharmacol 24:S1-6. 2004
  6. ncbi request reprint Impact of atypical antipsychotics on outcomes of care in schizophrenia
    Amie T Joyce
    PharMetrics Inc, 311 Arsenal Street, Watertown, MA 02472, USA
    Am J Manag Care 11:S254-61. 2005

Detail Information

Publications6

  1. ncbi request reprint Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study
    Antony D Loebel
    Pfizer Inc, New York, NY 10018, USA
    J Clin Psychiatry 68:1333-8. 2007
    ..To evaluate the efficacy, safety, and tolerability of long-term ziprasidone therapy in treatment-resistant schizophrenia...
  2. ncbi request reprint Effect of initial ziprasidone dose on length of therapy in schizophrenia
    Amie T Joyce
    PharMetrics, Inc, 311 Arsenal Street, Watertown, MA 02472, USA
    Schizophr Res 83:285-92. 2006
    ..To examine the effects of initial ziprasidone dose on discontinuation rates, using retrospective integrated medical and pharmacy claims data...
  3. ncbi request reprint Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia
    C Daniel Mullins
    University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    Schizophr Res 98:8-15. 2008
    ..To compare discontinuation rates of atypical antipsychotic agents in patients with schizophrenia...
  4. ncbi request reprint Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    Peter J Weiden
    Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Neuropsychopharmacology 33:985-94. 2008
    ..These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids...
  5. ncbi request reprint The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists
    John W Newcomer
    Department of Psychiatry and Psychology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychopharmacol 24:S1-6. 2004
    ..The impact of additional data and educational efforts in this area, such as a recently published consensus statement from the American Diabetes Association and other organizations, remains to be assessed...
  6. ncbi request reprint Impact of atypical antipsychotics on outcomes of care in schizophrenia
    Amie T Joyce
    PharMetrics Inc, 311 Arsenal Street, Watertown, MA 02472, USA
    Am J Manag Care 11:S254-61. 2005
    ..To compare persistence, compliance, and psychiatric treatment costs in patients who were initiated on atypical antipsychotics...